See more : Gensource Potash Corporation (GSP.V) Income Statement Analysis – Financial Results
Complete financial analysis of Simulations Plus, Inc. (SLP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Simulations Plus, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Robert Half International Inc. (RHI) Income Statement Analysis – Financial Results
- Farmacias Benavides, S.A.B. de C.V. (BEVIDESB.MX) Income Statement Analysis – Financial Results
- Logistec Corporation (LGT-B.TO) Income Statement Analysis – Financial Results
- Takaoka Toko Co., Ltd. (6617.T) Income Statement Analysis – Financial Results
- Fresh Express Delivery Holdings Group Co., Limited (1175.HK) Income Statement Analysis – Financial Results
Simulations Plus, Inc. (SLP)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.simulations-plus.com
About Simulations Plus, Inc.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.01M | 59.58M | 53.91M | 46.47M | 41.59M | 33.97M | 29.67M | 24.14M | 19.97M | 18.31M | 11.46M | 10.07M | 9.45M | 11.72M | 10.71M | 9.14M | 8.97M | 8.86M | 5.86M | 4.75M | 5.21M | 5.48M | 4.44M | 3.91M | 3.63M | 3.47M | 2.65M | 2.49M | 2.60M |
| Cost of Revenue | 26.86M | 11.63M | 10.82M | 10.60M | 10.65M | 9.03M | 7.99M | 6.31M | 4.60M | 4.32M | 1.63M | 1.65M | 1.51M | 2.88M | 2.55M | 2.32M | 2.10M | 2.08M | 1.60M | 1.51M | 1.56M | 1.54M | 1.46M | 1.56M | 1.16M | 1.65M | 1.76M | 1.25M | 1.20M |
| Gross Profit | 43.15M | 47.95M | 43.08M | 35.87M | 30.94M | 24.94M | 21.67M | 17.83M | 15.37M | 14.00M | 9.83M | 8.42M | 7.94M | 8.84M | 8.17M | 6.82M | 6.87M | 6.78M | 4.25M | 3.24M | 3.65M | 3.95M | 2.99M | 2.35M | 2.47M | 1.82M | 889.25K | 1.24M | 1.40M |
| Gross Profit Ratio | 61.63% | 80.48% | 79.92% | 77.19% | 74.39% | 73.43% | 73.05% | 73.87% | 76.96% | 76.43% | 85.79% | 83.65% | 84.02% | 75.44% | 76.23% | 74.61% | 76.58% | 76.49% | 72.60% | 68.27% | 70.09% | 71.96% | 67.23% | 60.08% | 67.98% | 52.45% | 33.62% | 49.77% | 53.85% |
| Research & Development | 5.75M | 4.50M | 3.21M | 4.05M | 2.97M | 2.50M | 1.79M | 1.37M | 1.45M | 1.33M | 952.77K | 802.37K | 947.56K | 935.20K | 969.87K | 1.11M | 990.49K | 814.95K | 445.25K | 524.56K | 515.02K | 379.63K | 382.14K | 354.09K | 299.88K | 218.51K | 390.45K | 133.02K | 100.00K |
| General & Administrative | 22.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.56M | 6.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 8.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 131.78K | 38.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.27M | 34.72M | 24.97M | 20.57M | 16.36M | 11.80M | 9.58M | 8.20M | 6.69M | 6.81M | 4.44M | 3.55M | 3.38M | 4.31M | 4.33M | 3.90M | 3.70M | 3.46M | 2.97M | 2.42M | 2.51M | 2.30M | 2.11M | 2.20M | 2.14M | 2.31M | 2.68M | 2.28M | 1.20M |
| Other Expenses | 0.00 | 2.97M | 204.00K | 0.00 | 14.30B | 14.30B | 8.14B | 0.00 | 0.00 | 0.00 | 0.00 | 35.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 261.15K | 0.00 | 0.00 | 0.00 | 100.00K |
| Operating Expenses | 37.02M | 39.22M | 28.17M | 24.61M | 19.33M | 14.30M | 11.37M | 9.57M | 8.14M | 8.14M | 5.39M | 4.35M | 4.33M | 5.24M | 5.30M | 5.01M | 4.69M | 4.27M | 3.42M | 2.95M | 3.02M | 2.68M | 2.49M | 2.55M | 2.70M | 2.53M | 3.07M | 2.41M | 1.40M |
| Cost & Expenses | 63.88M | 50.85M | 39.00M | 35.21M | 29.98M | 23.32M | 19.37M | 15.87M | 12.74M | 12.46M | 7.02M | 6.00M | 5.84M | 8.12M | 7.84M | 7.33M | 6.79M | 6.36M | 5.02M | 4.46M | 4.58M | 4.22M | 3.94M | 4.12M | 3.87M | 4.18M | 4.83M | 3.66M | 2.60M |
| Interest Income | 4.38M | 4.13M | 717.00K | 201.00K | 29.47K | 33.52K | 27.12K | 15.86K | 18.01K | 17.94K | 31.44K | 49.49K | 89.27K | 91.86K | 101.55K | 93.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 233.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 717.00K | 22.00K | 0.00 | 109.08K | 153.03K | 38.19K | 18.01K | 17.94K | 31.44K | 49.49K | 3.00 | 118.00 | 1.05K | 93.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.36K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.67M | 3.84M | 3.57M | 3.59M | 2.96M | 2.75M | 2.72M | 2.14M | 1.93M | 1.99M | 1.04M | 766.96K | 715.44K | 747.30K | 682.94K | 561.01K | 543.42K | 512.45K | 363.18K | 206.89K | 223.98K | 195.60K | 191.83K | 293.85K | 261.15K | 503.76K | 632.09K | 139.86K | -100.00K |
| EBITDA | 11.80M | 12.57M | 18.49M | 14.70M | 11.85M | 13.31M | 11.72M | 10.38M | 9.17M | 7.68M | 5.48M | 4.84M | 4.67M | 4.52M | 3.79M | 2.59M | 2.72M | 3.02M | 1.20M | 503.32K | 850.21K | 1.46M | 691.94K | 91.90K | 24.49K | -205.28K | -1.70M | -1.03M | 100.00K |
| EBITDA Ratio | 16.85% | 14.64% | 27.66% | 24.65% | 28.50% | 39.54% | 43.98% | 43.15% | 45.95% | 32.97% | 38.36% | 48.90% | 46.74% | 37.88% | 34.12% | 26.98% | 29.43% | 33.96% | 19.85% | 10.40% | 16.33% | 26.68% | 15.57% | 2.35% | 0.60% | -10.25% | -61.53% | -30.75% | 3.85% |
| Operating Income | 6.13M | 8.73M | 11.34M | 7.86M | 8.89M | 10.65M | 10.30M | 8.26M | 7.23M | 5.86M | 4.44M | 4.07M | 3.61M | 3.60M | 2.87M | 1.81M | 2.18M | 2.50M | 833.14K | 296.43K | 626.23K | 1.27M | 500.11K | -201.95K | -236.66K | -709.05K | -2.18M | -1.17M | 200.00K |
| Operating Income Ratio | 8.76% | 14.64% | 21.03% | 16.92% | 21.38% | 31.35% | 34.71% | 34.24% | 36.21% | 31.98% | 38.74% | 40.44% | 38.23% | 30.72% | 26.80% | 19.82% | 24.29% | 28.26% | 14.23% | 6.24% | 12.03% | 23.07% | 11.25% | -5.16% | -6.52% | -20.45% | -82.58% | -46.90% | 7.69% |
| Total Other Income/Expenses | 6.28M | 2.97M | 204.00K | -168.00K | 2.50M | -92.73K | -158.85K | -24.02K | 4.59K | -163.60K | 73.93K | 184.41K | 342.77K | 169.40K | 233.87K | 214.83K | 268.03K | 121.69K | 55.64K | 51.69K | 72.40K | -7.44K | -13.60K | -22.05K | -19.34K | 133.98K | 116.84K | -305.99K | 0.00 |
| Income Before Tax | 12.41M | 11.70M | 15.12M | 11.09M | 11.39M | 10.56M | 10.14M | 8.24M | 7.24M | 5.69M | 4.51M | 4.26M | 3.95M | 3.77M | 3.10M | 2.03M | 2.45M | 2.62M | 888.78K | 348.12K | 698.63K | 1.26M | 486.52K | -224.00K | -256.00K | -575.07K | -2.07M | -1.48M | 0.00 |
| Income Before Tax Ratio | 17.73% | 19.63% | 28.04% | 23.86% | 27.38% | 31.08% | 34.18% | 34.14% | 36.23% | 31.08% | 39.38% | 42.27% | 41.85% | 32.17% | 28.98% | 22.17% | 27.28% | 29.63% | 15.18% | 7.32% | 13.42% | 22.94% | 10.95% | -5.72% | -7.05% | -16.59% | -78.17% | -59.17% | 0.00% |
| Income Tax Expense | 2.46M | 1.73M | 2.63M | 1.30M | 2.05M | 1.97M | 1.20M | 2.45M | 2.29M | 1.85M | 1.49M | 1.37M | 1.14M | 1.06M | 948.43K | 614.58K | 720.61K | 1.16M | 212.90K | 85.80K | -137.86K | -1.25M | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | -38.80K | 0.00 |
| Net Income | 9.95M | 9.96M | 12.48M | 9.78M | 9.33M | 8.58M | 8.93M | 5.79M | 4.95M | 3.84M | 3.03M | 2.89M | 3.03M | 2.71M | 2.16M | 1.41M | 1.73M | 1.47M | 675.88K | 262.32K | 836.49K | 2.51M | 484.92K | -225.60K | -257.60K | -576.67K | -2.07M | -1.44M | 0.00 |
| Net Income Ratio | 14.22% | 16.72% | 23.16% | 21.05% | 22.44% | 25.27% | 30.12% | 23.98% | 24.79% | 20.98% | 26.40% | 28.66% | 32.05% | 23.16% | 20.13% | 15.44% | 19.24% | 16.55% | 11.54% | 5.52% | 16.07% | 45.69% | 10.91% | -5.76% | -7.10% | -16.63% | -78.23% | -57.62% | 0.00% |
| EPS | 0.50 | 0.50 | 0.62 | 0.49 | 0.52 | 0.49 | 0.52 | 0.34 | 0.29 | 0.23 | 0.19 | 0.18 | 0.19 | 0.17 | 0.14 | 0.09 | 0.11 | 0.10 | 0.05 | 0.02 | 0.06 | 0.18 | 0.04 | -0.02 | -0.02 | -0.04 | -0.62 | -0.49 | 0.00 |
| EPS Diluted | 0.49 | 0.49 | 0.60 | 0.47 | 0.50 | 0.48 | 0.50 | 0.33 | 0.29 | 0.23 | 0.18 | 0.18 | 0.19 | 0.17 | 0.13 | 0.08 | 0.10 | 0.08 | 0.04 | 0.02 | 0.05 | 0.17 | 0.03 | -0.02 | -0.02 | -0.04 | -0.62 | -0.49 | 0.00 |
| Weighted Avg Shares Out | 19.99M | 20.08M | 20.20M | 20.05M | 17.82M | 17.49M | 17.33M | 17.24M | 17.03M | 16.86M | 16.17M | 16.00M | 15.76M | 15.54M | 15.83M | 16.13M | 16.13M | 15.28M | 14.72M | 14.44M | 13.98M | 13.64M | 13.63M | 13.58M | 13.54M | 13.51M | 3.33M | 2.94M | 2.22M |
| Weighted Avg Shares Out (Dil) | 20.30M | 20.47M | 20.75M | 20.74M | 18.54M | 18.06M | 17.86M | 17.52M | 17.21M | 17.03M | 16.41M | 16.32M | 16.15M | 16.08M | 16.51M | 17.19M | 18.14M | 17.96M | 16.29M | 15.92M | 15.58M | 14.96M | 14.10M | 13.58M | 13.54M | 13.51M | 3.33M | 2.94M | 2.22M |
Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, in partnership with USC, is awarded a new research grant from the NIH to develop new AI-driven Drug Design methods.
Simulations Plus (SLP) Restructures Business Unit Post-Acquisitions
Simulations Plus, Inc. SLP has streamlined its business unit and leadership structure to foster growth after recent acquisitions. These updates will be implemented on Aug 30, 2024.
Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced strategic changes in leadership and the structure of its business units to optimize operations and support future growth.
Simulations Plus (SLP) Ties Up With ICCS for Chemical Safety
Simulations Plus, Inc. SLP has entered into a partnership with the International Collaboration on Cosmetics Safety (“ICCS”) to develop a physiologically-based kinetic (PBK) read-across strategy for diverse chemicals and exposure routes (intravenous, oral and dermal) across virtual populations of humans...
Simulations Plus Stock Drops 15% Despite EPS Beat
Simulations Plus NASDAQ: SLP is a small-cap healthcare technology company with a value of about $800 million. The firm has vastly underperformed the market and its sector over the last 12 months, with a total return of -7%.
Simulations Plus (SLP) Q3 Earnings & Revenues Beat Estimates
Simulations Plus' (SLP) fiscal third-quarter revenues are driven by strength in Software and Services units.
Simulations Plus Posts Q3 Results, Joins First Foundation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 0.2% on Wednesday.
Simulations Plus, Inc. (SLP) Q3 2024 Earnings Call Transcript
Simulations Plus, Inc. (NASDAQ:SLP ) Q3 2024 Earnings Conference Call July 2, 2024 5:00 PM ET Company Participants Lisa Fortuna - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer & Chief Operating...
Analysts Estimate Simulations Plus (SLP) to Report a Decline in Earnings: What to Look Out for
Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simulations Plus to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, will be participating in Morgan Stanley's 3rd Annual Life Sciences AI Summit on June 26, 2024, in New York City.
Source: https://incomestatements.info
Category: Stock Reports